Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
On my watch list , if it gets anywhere near £1.50 , I will buy ££50k worth but not yet .
Does slightly take the shine off all those director buys recently. With 40% of the award based on share price performance at least that's one chunk they're unlikely to be gifted. The other big chunk being purely revenue based is a bit discomforting though, that can always be juiced if bottom line not taken into account.
You couldn’t make it up ! “The LTIP awards are subject to performance conditions. As set out in the 2022 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2023, 2024 and 2025) and strategic milestones (20% of the award)”.
Could it be that this is a loss making company and profit is not exactly around the corner. Cash burn is always a concern ! Due to the complexity of their finances anyone know what’s in the bank ?
Over the years I've seen OXB crash like this several times but they always bounced back after a surprise bail out package however they are not bouncing yet, so this one looks a bit odd. I will need to read their next financial report to get a better understanding why this time is different but my suspicion is they can't afford the extra cash burn from OXB US, there also used to be a subsidiary in the US in the past but they were also closed down due to running costs 🤔
Can anyone please clarify how many shares Vulpes has sold in the last few months?
It’s going to take one hell of a Santa rally to stop the rot here… what are the management doing?
Weird thing is Novo stake building should have compensated, Vulpes tiny players in comparison. But with it being a decade long hold for them, they must have been aware optics more significant than the average II here, especially if they're selling into multi year lows.
Could be worse though, at obd they've gone for a maddening drip drip selling strategy with gradual release RNSs, almost as if it was designed to maximise a fall. Looks terrible when they have a board seat. But I'm assuming they're either facing a pretty urgent need to liquidate, or having seen a fortune evaporate post-covid, no longer give a sh*t. Maybe both.
unfortunately the proposed business change in direction is going to take a considerable time, if it indeed works, so not sure where the sp is going to end up in the meantime. the bod have made a few strange decisions over the last year with ****logy being one !
just when you think the sp has started to level out it drops again so can’t see any new money coming in to stop the rot. calling bottom is impossible at the moment and it would seem that the market has very little faith in the bod.
Unless of course they do know how it looks and are taking what they can when they can.
Still holding as the loss for me would be very large and hopefully the new people can pull some thing out of the bag.
It's been carnage here, considered buying in a few times into what look likes a bottom but fall pretty relentless. Wonder if it's still Vulpes selling. As with OBD having held so long for them to start selling recently is hard to make sense of. Unless they're forced sellers they must know how it looks.
Still seems to be a large seller offloading for whatever reason !
Hi Kern,
As you say the consolidation was supposed to put an end to these swings and unfortunately one sunny day doesn’t make a summer. Mainly in banks and Aviva at the moment but they are also dropping like a stone on the mere hint of anything negative. Santa rally seems unlikely this year the way the world is !
OXB has good write up in The Times today, manifesto section.
Shatter
it's inexorable so yes I can't see why it won't fall below £2.
The boost from the last announcement is long gone as we don't see any progress. Give them time of course but the market seems to have made up its mind.
Remember the consolidation was supposed to put an end to these wild swings but £15 to just over £2 is pretty wild in my eyes.
OXB not the only one to be decimated as Angle went from £1.50 to 11p when the CEO rubbished the company and the pi's.
All biotecs languishing atm as it is an unloved sector so companies need results to change the sp direction not just aspirations and words.
We'll probably see Novo buying again. Good climate for them.
Almost all samallcaps, AIM and to some extent FT250 shares go up with some very positive news. Then after couple of days later, they drop about 5% a day until the drop past previous level before rise. This is sickening for long term investers.
This is being deliberately dropped, perhaps shorted, but when you get so many small sells all occurring in the same second week after week something is array. Every share has its ups and downs and is usually news driven but this is ridiculous.
What’s to stop this going sub £2.00 in the near future? The markets are in turmoil. My portfolio recovered a little but is going to rats again..gl all
Always a good sign.
Market clearly doesn't believe so. Almost 5% again today.
Preparing for the worst!
This has been a rudderless ship going in every direction for the last couple of years. Interesting to see if this new direction can turn a profit in a couple of years…
Well that burst of optimism seems to have dissipated. Back to watching daily drops.
A highly effective malaria vaccine has been recommended for widespread use by the World Health Organization.
The R21/Matrix-M vaccine, developed by the University of Oxford, is only the second malaria vaccine to be recommended by the WHO. It is the first to meet the WHO’s target of 75% efficacy. Malaria, a mosquito-borne disease, claims half a million lives every year and mostly affects children under the age of five, and pregnant women. “As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two,” said Dr Tedros Adhanom Ghebreyesus, director general of the WHO. Demand for vaccines is huge. However, available supplies of the RTS,S vaccine, the first malaria vaccine approved by the WHO in 2021, are limited. A second WHO-recommended vaccine is expected “to protect more children faster, and to bring us closer to our vision of a malaria-free future,” said Tedros.
The RTS,S vaccine will be available in some African countries in early 2024 and the R21 malaria vaccine is expected to become available to countries in mid-2024. The world’s largest vaccine manufacturer by doses – the Serum Institute of India – is already lined up to make more than 100m doses a year and plans to scale up to 200m a year, the BBC reported. Each dose costs between $2 and $4; four doses are needed per person. That is about half the price of RTS,S. So far, there are only 18m doses of RTS,S. (Guardian)
Keep calm & Carry on?